Currently, there are 207.34M common shares owned by the public and among those 12.71M shares have been available to trade.
The company’s stock has a 5-day price change of 35.15% and -24.92% over the past three months. CYCC shares are trading -24.12% year to date (YTD), with the 12-month market performance down to -87.60% lower. It has a 12-month low price of $0.17 and touched a high of $4.00 over the same period. CYCC has an average intraday trading volume of 345.49K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 21.89%, -0.52%, and -58.21% respectively.
Institutional ownership of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares accounts for 0.34% of the company’s 207.34M shares outstanding.
It has a market capitalization of $59.15M and a beta (3y monthly) value of 0.51. The earnings-per-share (ttm) stands at -$5.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 25.28% over the week and 15.37% over the month.
Analysts forecast that Cyclacel Pharmaceuticals Inc (CYCC) will achieve an EPS of 0 for the current quarter, 0 for the next quarter and 0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0 while analysts give the company a high EPS estimate of 0.
Looking at the support for the CYCC, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on July 18, 2022, with the firm’s price target at $17. ROTH Capital coverage for the Cyclacel Pharmaceuticals Inc (CYCC) stock in a research note released on April 27, 2020 offered a Buy rating with a price target of $24. Ladenburg Thalmann was of a view on September 07, 2018 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on October 16, 2015, issuing a price target of $5. Roth Capital on their part issued Buy rating on February 04, 2010.
